Let’s begin by saying that any investment is risky. When you invest, only do so on your own due diligence. Anything can happen: When Covid news went worldwide in March 2020,
even the greats tumbled. Tesla fell to $103. Boeing fell to $113 pre-market, $145 avg EOD.
Having said that, with Covid hopefully and largely a thing of the past, we wish to share our research and thoughts on the top 5 most undervalued stocks, after our deep dive of due diligence.
#1: INPX Inpixon.
According to Yahoo Finance, the split and dilution adjusted price was $2,686.50 in April 2019. The company has grown and grown, is spinning off Damon motorcycles, which is setting major dyno and other speed records, already spun off CXApp Inc, which had a major run shortly after its birth. It is now set to merge with XTI, an electric aircraft company, which has $7.1 B in pre-orders. Closing was stated to complete by 3-31-2024.
PT=$1.31/sh
#2 HKD AMTD Digital
The legend, the all time 3 day gainer, went from $10 to $2,550 in early August 2022. Inexplicably it has fallen below $4/sh, and the company has not diluted, in fact it has bough back $40 million in shares in the last 2 quarters.
It’s just a matter of time for this now French company, who had 3 major box office movie hits recently, and boasts a proud WSJ
Tangible book value of $16.75/sh
#3 HOLO MicroCloud Hologram Inc
Recently this stock did a mini HKD run, approx 1/3 of it in one day, reaching from $1.50 to $113. It is set to join a communications group, with their amazing holographic ChatGPT similation, and already offer
their services to an unknown EV maker in China, likely BYD.
With a micro float of 1.1m, its volume and volatility are legendary already. Any day, anything can happen. But even
long term holders can be rewarded, as the future of this
company is so bright, all their employees and investors should wear shades.
(Since our writing this, Elon Musk has followed our Twitter page!…hmmm. Hint?)
PT=$37/sh
#4 LQR Liquor House Recently performing a 50% dividend
in shares, and receiving many new orders, the future is
unlimited for this company. With a vibrant CEO, valued partnerships, and loyal investor base, this should quadruple
or more soon
PT=$8/sh
#5 ATHA Athira Pharma, Inc.
We needed a pharma stock for this list, and SBFM came in a close second to Athira. The financials are strong for a clinical pharma, with very little debt, the catalysts and insider chatter for its Alzheimer’s treatments are extremely strong.
PT=$12/sh
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Companies’ current expectations and projections about future events that the Companies believe may affect its financial condition, results of operations, business strategy and financial needs. Shareholders can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. The Companies undertake no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the “Risk Factors” section of the registration statements on Form S-1 filed with the SEC and other filings with the SEC. Although the Companies believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Companies cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Companies; registration statements and other filings with the SEC. Additional factors are discussed in the Companies’ filings with the SEC, which are available for review at www.sec.gov.
Read Original Article.